NCT Number: NCT02146391
Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal
This study is an open-label, randomized, single-center, single-dose, two-way crossover study of the PK properties of Androxal in healthy male subjects. Twelve male subjects will each receive a single dose of Androxal 25 mg in both the fed and fasting state.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–60 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
- Male; age 18-60 with a BMI of 25-42 kg/m2 inclusive
- No significant abnormal findings at the screening physical examination as evaluated by the Investigator;
- Normal laboratory values (or abnormal but not clinically significant) at screening as determined by the Investigator;
- Subject is willing to remain in the clinic for the screening visit and 2 overnight treatment visits (approximately 36 hours for the treatment visit)
- Must be able to swallow gelatin capsules;
- Must be willing to remain in the clinic for the treatment visits
Exclusion criteria
- Known hypersensitivity to Clomid;
- Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Investigator;
- A hematocrit >54% or a hemoglobin >17 g/dL.
- Subject with a significant organ abnormality or disease as determined by the Investigator;
- Any medical condition that would interfere with the study as determined by the Investigator;
- Participation in a clinical trial with investigational medication within 30 days prior to study medication administration;
- An acute illness within 5 days of study medication administration;
- Positive urine drug screen at the screening visit;
- Known history of HIV and/or Hepatitis B or C
- Tobacco (nicotine products) use in the 3 months prior to the study;
- A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study and/or evidence of an uncooperative attitude, as determined by the Investigator;
- History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary embolism);
- History of myocardial infarction, unstable angina, symptomatic heart failure, ventricular dysrhythmia, or known history of QTc interval prolongation;
- An employee or family member of an employee of the study site or the Sponsor;
- Previous participation in a clinical study of Androxal.
Treatment and study plan
Primary outcomes
-
• Cmax of a single dose of 25 mg of Androxal in male subjects in the fed state and fasted state.
Time frame: 24 hour
Sponsors and collaborators
Lead sponsor
Repros Therapeutics Inc.
Industry
Registry information
Official study title
AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- May 23, 2014
- Registry last updated
- Aug 11, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Fatty Acid Oxidation Defects and Insulin Sensitivity
NCT02517307
Carnitine Palmitoyltransferase II Deficiency, Late-Onset, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Portland, Oregon, United States
View Trial DetailsThe Effect of Head and Shoulder Positioning on the Cross-sectional Area of the Subclavian Vein in Obese Adults
NCT03993587
Normal Volunteers
Seoul, South Korea
View Trial DetailsPharmacokinetics and Bioavailability Comparison of Two Different Formulations of MNTX Tablets
NCT01366352
Normal Volunteers
Tarrytown, New York, United States
View Trial DetailsNeural Mechanisms of Motor and Cognitive Networks
NCT02828813
Cognition Disorders, Mental Disorders
Beijing, China
View Trial Details